Skip to content

Atomwise

9 viewers · 30d

Total raised

$64.1M

+$19.8M this year

2 filings since 2024 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $19.8M
ROUNDS
2
INVESTORS
19
FOUNDED
N/A
HQ
San Francisco, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
9

AI overview

Updated

Atomwise Inc. is a pioneering technology-enabled pharmaceutical company that employs artificial intelligence to transform the landscape of small molecule drug discovery. By leveraging advanced machine learning techniques, Atomwise aims to streamline the drug development process, making it not only more efficient but also more effective in identifying viable therapeutic candidates.

What sets it apart

Atomwise stands out for its innovative use of AI to significantly reduce the time and cost traditionally associated with drug discovery while enhancing the likelihood of success.

Funding history

2 rounds
Equity+1Mar 10, 2026
Form D
+$19.8M$64.1M total
Equity+1Mar 8, 2024
Form D
+$44.3M$44.3M total

Products

1 tracked

AtomNet

Drug Discovery

AtomNet is an advanced AI-powered drug discovery platform that utilizes deep learning algorithms and convolutional neural networks to predict interactions between small molecules and protein targets. This cutting-edge technology enables the virtual screening of billions of chemical compounds, rapidly identifying the most promising candidates for further development.

  • Rapid virtual screening of billions of compounds
  • Predictive modeling of molecule-protein binding affinities
  • Deep learning and convolutional neural network technology
  • Support for a wide range of therapeutic areas